March 1, 2019
The Ministry of Health, Labor and Welfare (MHLW) issued a notification on February 28 informing of a label revision for AstraZeneca’s EGFR tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) regarding its risk of interstitial lung disease (ILD). In its warning section,...read more